The global plasma protease C1 inhibitor market is projected to reach USD 10,715.3 million by 2028, growing at a CAGR of 17.7%. Growing emphasis of biopharmaceutical companies on the development of effective therapies for treating various health disorders, increasing product consents and increasing research & development are some of the factors driving the growth of the global plasma protease C1 inhibitor market.
Adroit Market Research report on global Plasma protease C1 inhibitor market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global plasma protease C1 inhibitor market have been studied in detail.
The global plasma protease c1 inhibitor market is categorized based on drug type and dosage form. On the basis of drug type, the market is segmented into c1-inhibitors, kallikrein inhibitor and selective bradykinin b2 receptor antagonist. The C1-inhibitors dominated the market in 2020. On the basis of dosage form, the market is segmented into lyophilized and injectable.
North America dominated the market for plasma protease C1 inhibitor in 2020, while Asia-Pacific is set to grow at the highest CAGR due to increasing R&D investments. Key players of the global plasma protease C1 inhibitor market include KalVista Pharmaceuticals, Inc., CSL Behring LLC, Lonis Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., BioCryst Pharmaceuticals, Centogene AG, among others.
Key segments of the global plasma protease C1 inhibitor market
Drug Type Overview, 2018-2028 (USD Million)
- Kallikrein inhibitor
- Selective bradykinin b2 receptor antagonist
Dosage Form 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Asia Pacific
- South America
- Middle East & Africa
- South Africa